Disc Medicine, Inc.
NNASDAQ:IRONRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Disc Medicine, Inc. (Nasdaq: IRON) develops novel therapies targeting red blood cell biology pathways, including heme biosynthesis and iron homeostasis, for patients with serious hematologic diseases such as anemias and polycythemia. The company offers a clinical-stage pipeline featuring bitopertin, a glycine transporter 1 inhibitor for erythropoietic porphyrias including erythropoietic protoporphyria and X-linked protoporphyria, as well as Diamond-Blackfan anemia; DISC-0974, a hepcidin inhibitor for anemia of myelofibrosis and anemia of chronic kidney disease; DISC-3405, a monoclonal antibody against transmembrane serine protease 6 licensed from Mabwell Therapeutics for polycythemia vera and other myeloproliferative neoplasms; and preclinical DISC-0998 for anemia associated with inflammatory diseases. Disc Medicine conducts operations in the United States and pursues global development opportunities through clinical trials and regulatory submissions. Founded in 2017, the company maintains headquarters at 321 Arsenal Street, Suite 101, Watertown, Massachusetts. Recent developments include submission of a New Drug Application for accelerated approval of bitopertin in erythropoietic protoporphyria on September 29, 2025, following a positive pre-NDA meeting with the FDA and receipt of a Commissioner's National Priority Voucher in October 2025; an upsized $250 million public offering in late 2025 raising approximately $211 million in net proceeds to extend cash runway into 2029; completion of a $200 million non-dilutive debt financing facility with Hercules Capital in 2024 providing up to $110 million in available funding; presentation of initial Phase 2 data for DISC-0974 in myelofibrosis anemia and DISC-3405 in polycythemia vera at the ASH Annual Meeting in December 2025; and advancement of multiple ongoing trials including Phase 1b DISC-3405 in sickle cell disease initiated in October 2025.
Company News
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
Disc Medicine stock soars: take profit or buy into strength?
Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatment
Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes
Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
Disc Medicine's rare disease drug succeeds in late-stage trial
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
ROSEN, A LEADING NATIONAL FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON